Abstract
Cordyceps militaris has been used in Eastern countries for the treatment of various diseases including chronic kidney diseases. However, there are no reports that identified its active entities and molecular mechanisms underlying its therapeutic effectiveness. 3′-Deoxyadenosine is a major nucleoside derivative isolated from C. militaris. Some reports suggested that both C. militaris and 3′-deoxyadenosine have anti-inflammatory and anti-fibrotic effects. In the present report, we investigated whether and how 3′-deoxyadenosine interferes with fibrogenic processes in the kidney. For this purpose, we examined effects of 3′-deoxyadenosine on the expression of collagens triggered by transforming growth factor-β (TGF-β1) and bone morphogenetic protein-4 (BMP-4), especially focusing on the regulation of Smad signaling in vitro and in vivo. We found that 3′-deoxyadenosine suppressed expression of collagens induced by TGF-β1 and BMP-4 dose dependently. This suppression occurred at the transcriptional level and was correlated with blunted activation of the CAGA box and the BMP-responsive element. The suppressive effect on the TGF-β/BMP signaling was mediated mainly by adenosine transporter and partially by the A3 adenosine receptor, but not A1/A2 adenosine receptors. 3′-Deoxyadenosine reduced levels of both phosphorylated and total Smad proteins (Smad1, 2 and 3) dose dependently. It was mainly ascribed to transcriptional suppression, but not to enhanced protein degradation and eIF2α-mediated translational suppression. Consistent with the in vitro results, in vivo administration with 3′-deoxyadenosine reduced the levels of phosphorylated and total Smad proteins, as well as the levels of Smad mRNAs, in the kidney subjected to unilateral ureteral obstruction. It was associated with blunted induction of type I collagen and α-smooth muscle actin, a decrease in the number of interstitial myofibroblasts and reduced fibrotic area. These results suggest that 3′-deoxyadenosine interferes with the TGF-β and BMP signaling via downregulation of Smads, which may underlie the anti-fibrotic effect of this agent. 3′-Deoxyadenosine may be useful for therapeutic intervention in various TGF-β-related fibrotic disorders.
Similar content being viewed by others
Main
Cordyceps militaris is a medicinal mushroom that has been considered as an abundant source of bioactive substances. It possesses various biological activities including anti-inflammatory, anti-tumor, anti-microbial, anti-fibrotic and neuroprotective effects.1 Because of this reason, C. militaris has been used in Eastern countries for the treatment of various diseases, including chronic kidney diseases.2 However, there are few reports that showed pharmacological mechanisms underlying its clinical utility and therapeutic effectiveness.
Tubulointerstitial fibrosis is an end-stage feature of a wide range of chronic kidney diseases. Members of the transforming growth factor-β (TGF-β) superfamily have important roles in the progression of tissue fibrosis by inducing epithelial-to-mesenchymal transition, chronic inflammation, activation of interstitial myofibroblasts and accumulation of extracellular matrix.3, 4 In particular, prototypic TGF-β1 and bone morphogenetic protein-4 (BMP-4) have important roles in the regulation of tissue fibrosis and sclerosis.5, 6, 7 During the past decades, the signal transduction pathways triggered by the TGF-β superfamily have been extensively investigated. TGF-βs and BMPs bind to their receptors and activate Smad2/3 and Smad1/5/8, respectively.8 These receptor-activated Smads (R-Smads) are phosphorylated directly by receptor kinase and induce association and formation of heterotrimeric complex of two R-Smads and a common Smad protein (eg, Smad4), leading to their translocation to the nucleus.9, 10 Smad3 and Smad4 preferentially bind to a specific DNA sequences, namely the CAGA box, whereas Smad1 binds to the BMP-responsive element (BRE), leading to transcriptional induction of their target genes including collagens.11, 12
Recent studies indicated potential roles of adenosine in renoprotection from ischemic injury. In the kidney, adenosine acts through adenosine receptors and has a critical role in regulating renal inflammation and ischemic kidney disease.13 Four adenosine receptor subtypes, including A1, A2A, A2B and A3, are detectable in the kidney. Activation of these receptors has both beneficial and deteriorative effects on renal pathophysiology, as recently reviewed by Yap and Lee.14
3′-Deoxyadenosine, also called cordycepin, is an analogue of adenosine and was identified as a major bioactive constituent in C. militaris15, 16 and possesses a wide range of biological effects, including anti-cancer, anti-inflammatory and anti-mitogenic effects.17, 18, 19 Nan et al.20 reported that biopolymers produced by C. militaris inhibited experimental liver fibrosis in rats. A recent report indicated that 3′-deoxyadenosine could affect Smad2/3 signaling, but underlying mechanisms are largely unknown.21 In the present study, we examine the anti-fibrogenic potential of 3′-deoxyadenosine in the kidney, especially focusing its effect on the Smad signaling pathways. Our current results reveal for the first time that 3′-deoxyadenosine interferes with TGF-β and BMP signaling via downregulation of Smads in vitro and in vivo.
MATERIALS AND METHODS
Reagents
3′-Deoxyadenosine, adenosine, 1,3-dipropyl-8-(p-sulfophenyl)xanthine (DPSPX; A1/A2 adenosine receptor antagonist), MRS1523 (A3 adenosine receptor antagonist), 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA; adenosine A3 receptor agonist), S-(4-Nitrobenzyl)-6-thioinosine (NBTI; adenosine transport inhibitor) and actinomycin D were purchased from Sigma-Aldrich Japan (Tokyo, Japan). ATP, ADP and chloroquine diphosphate were obtained from Wako Pure Chemical (Osaka, Japan), salubrinal (inhibitor of eukaryotic initiation factor 2α (eIF2α) dephosphorylation) was from Tocris Bioscience (Ellisville, MO, USA), MG132 was from Peptide Institute (Osaka, Japan), and human TGF-β1 and human recombinant BMP-4 were from R&D Systems (Minneapolis, MN, USA). Throughout the study, 5 μg/ml of 3′-deoxyadenosine was generally used for experiments, because this concentration is non-toxic to NRK-52E cells and has the maximum biological effects, including suppression of endoplasmic reticulum stress-induced apoptosis and inhibition of NF-κB activation.22, 23
Cell Culture
The rat renal tubular epithelial cell line NRK-52E was purchased from American Type Culture Collection (Manassas, VA, USA). SM43 rat mesangial cells were established as described previously.24 Cells were cultured in Dulbecco’s modified Eagle’s medium/Ham’s F-12 (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 5% fetal bovine serum (FBS). Experiments were performed in the presence of 1% FBS.
Northern Blot Analysis
Total RNA was extracted by a single-step method, and Northern blot analysis was performed as described before.22 cDNAs for procollagen α1(IV),25 procollagen α1(I),26 α-smooth muscle actin (α-SMA),27 Smad1, Smad2 and Smad3 (provided by Dr Keiji Miyazawa, University of Yamanashi) were used to prepare radio-labeled probes. Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 28S ribosomal RNA were used as loading controls. Densitometric analysis was performed using ImageJ Software (National Institutes of Health, Bethesda, MD, USA).
Western Blot Analysis
Western blot analysis was performed as described before.28 Levels of phosphorylated and total proteins of Smad1, Smad2 and Smad3 were assessed using anti-phospho Smad1 (Ser206) antibody, anti-Smad1 antibody, anti-phospho Smad2 (Ser465/467) antibody, anti-Smad2 antibody, anti-phospho Smad3 (Ser423/425) antibody and anti-Smad3 antibody (Cell Signaling, Beverly, MA, USA). Anti-phospho eIF2α (Ser51) antibody was purchased from Cell Signaling, and anti-eIF2α antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The level of β-actin and α-SMA was assessed using anti-β-actin antibody (Sigma-Aldrich, Japan) and anti-α-SMA antibody (Dako, Tokyo, Japan). Blots were visualized using the enhanced chemiluminescent system (Amersham Biosciences, Buckinghamshire, UK). Densitometric analysis was performed using ImageJ Software.
Reporter Assay
Using electroporation, NRK-52E cells were transiently transfected with p(CAGA)12-MLP-Luc (provided by Dr Atsuhito Nakao, University of Yamanashi)11 or pBRE-Luc (provided by Dr Keiji Miyazawa, University of Yamanashi),12 treated with TGF-β1 or BMP-4 in the absence or presence of 3′-deoxyadenosine and subjected to luciferase assay. In some experiments, pcDNA3.CD2-heIF2α-S51A encoding a dominant-negative mutant of eIF2α (eIF2α-DN) (provided by Dr David Ron, University of Cambridge)29 or pcDNA3.1-GADD34 coding for growth arrest and DNA damage gene 34 (GADD34) (provided by Dr Takeshi Omasa, Osaka University)30 was co-transfected to evaluate involvement of eIF2α. pGL2-F-1005/+93Smad1 that introduces a luciferase gene under the control of the Smad1 gene promoter (provided by Dr Yuewen Gong, University of Manitoba)31 was also used to evaluate the effect of 3′-deoxyadenosine. pSV40-Luc that introduces a luciferase gene under the control of the simian virus 40 (SV40) promoter (provided by Dr Takahiro Taira, University of Yamanashi) was used for control experiments. Using GeneJuice (Novagen, Madison, WI, USA), NRK-52E cells were also transfected with p(CAGA)12-MLP-Luc or pBRE-Luc together with A2B adenosine receptor siRNA (sense, 5′-AACAGUAAAGACCGUGCCA-3′; antisense, 3′-UUGUCAUUUCUGGCACGGU-5′) (Takara, Shiga, Japan), A3 adenosine receptor siRNA (Silencer Select Pre-designed siRNA; Ambion, Austin, TX, USA) or control siRNA (sense, 5′-GCUGCAAUCGAUUGAUAGC-3′; antisense, 3′-CGACGUUAGCUAACUAUCG-5′) (Takara). The cells were then treated with or without 3′-deoxyadenosine and subjected to luciferase assay.
Luciferase Assay
Activity of luciferase was evaluated by Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer’s protocol.32 Assays were performed in quadruplicate.
Formazan Assay
The number of viable cells was assessed by formazan assay using Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). Assays were performed in quadruplicate.
Animal Experiment
PBS or 3′-deoxyadenosine (5 mg/kg) was injected intraperitoneally into C57BL/6 mice (20–25 g body weight) on day 0, 1, 2 and 3. On day 1, unilateral ureteral obstruction (UUO) was performed, as described previously.33 In brief, the proximal part of the left ureter was exposed under anesthesia and ligated completely with a 5.0 silk thread at two separate points (UUO groups; severe ligature). In sham-operated groups, the left ureter was exposed, and the incision was closed without ligation. Three to seven days after the UUO (day 3 and 7), left kidneys were removed and processed for histopathological analysis, immunohistochemistry and northern/western blot analyses.34 In some experiments, partial UUO (mild ligature) was induced using a nylon thread (0.6 mm in diameter).35 Individual groups contained 3–4 mice. Animal experiments were approved by the local institutional review board for the care of animal subjects.
Histopathological Analysis and Immunohistochemistry
Kidneys were fixed in 4% phosphate-buffered paraformaldehyde overnight at 4 °C, embedded in paraffin and subjected to tissue sectioning. The sections were stained by hematoxylin, periodic acid-Schiff or Masson’s trichrome. Using Masson’s trichrome staining, the area of fibrosis (blue area) was evaluated by LuminaVision V2.04 software (Mitani, Fukui, Japan). Immunohistochemical analysis was performed using anti-α-SMA antibody. Peroxidase reaction was performed using 3,3′-diaminobenzidine tetrahydrochloride.
Statistical Analysis
Reporter assays were performed in quadruplicate. Northern and western blot analyses were repeated 2–3 times independently (or performed in triplicate or in quadruplicate), and individual data were subjected to densitometric analysis. Data were expressed as means±s.e. Statistical analysis was performed using the non-parametric Mann–Whitney U-test to compare data in different groups. A P-value <0.05 was considered to indicate a statistically significant difference.
RESULTS
Suppression of TGF-β and BMP-4 Signaling by 3′-Deoxyadenosine
TGF-β family members including TGF-β1 and BMP-4 regulate production of extracellular matrix, such as collagens.36 To examine whether 3′-deoxyadenosine has the potential to influence TGF-β signaling, we first examined effects of 3′-deoxyadenosine on TGF-β1- and BMP-4-induced collagen gene expression. When NRK-52E cells were treated with TGF-β1 or BMP-4, expression of type I collagen mRNA was upregulated. The induction of type IV collagen was only minimum. Treatment with 3′-deoxyadenosine suppressed transcriptional expression of both collagens (Figure 1a and Supplementary Figure S1), and the effects were dose dependent (Figure 1b and Supplementary Figure S2). Of note, treatment with 3′-deoxyadenosine also reduced basal levels of type I and type IV collagens (Figure 1a) that may be maintained by platelet-derived TGF-β1 contained in FBS.37
TGF-β1 and BMP-4 regulate expression of target genes via activation of the CAGA box and BRE.7 We next tested effects of 3′-deoxyadenosine on the activation of the CAGA box and BRE by TGF-β1 and BMP-4. Reporter assay showed that TGF-β1 and BMP-4 significantly induced activation of the CAGA box and BRE, respectively. 3′-Deoxyadenosine blocked the activation of these responsive elements (Figures 1c and d). This suppressive effect was not ascribed to non-specific effects on transcription and/or translation, because activity of luciferase driven by the SV40 promoter was not influenced by the treatment with 3′-deoxyadenosine (Figure 1e).
3′-Deoxyadenosine is an analogue of adenosine. Other adenosine-related substances may mimic the effects of 3′-deoxyadenosine. To examine this possibility, effects of adenosine, ADP and ATP were tested. The results showed that, in contrast to 3′-deoxyadenosine, ATP and ADP did not inhibit TGF-β1- and BMP-4-induced activation of the CAGA box (Figure 1f) and BRE (Figure 1g), respectively. Adenosine slightly reduced activation of the CAGA box and BRE, whereas the suppressive effect was much less than that of 3′-deoxyadenosine (Figures 1f and g).
Roles of Adenosine Receptors and Adenosine Transporter in the Suppression of TGF- β and BMP-4 Signaling by 3′-Deoxyadenosine
We previously reported that 3′-deoxyadenosine modulated stress responses via the A3 adenosine receptor and adenosine transporter.22 To elucidate mechanisms underlying the suppressive effects of 3′-deoxyadenosine on TGF-β1 and BMP-4 signaling, roles of adenosine receptors and adenosine transporter were examined. For this purpose, A1/A2 adenosine receptor antagonist DPSPX, A3 adenosine receptor antagonist MRS1523 and adenosine transport inhibitor NBTI were used. Northern blot analysis showed that the suppressive effect of 3′-deoxyadenosine on the induction of collagens by TGF-β1 was reversed by MRS1523 and NBTI (Figure 2a and Supplementary Figure S3a). In contrast, DPSPX did not affect the suppressive effect of 3′-deoxyadenosine. The suppressive effect of 3′-deoxyadenosine on TGF-β1-triggered CAGA activation was also reversed by NBTI, whereas DPSPX and MRS1523 did not influence the effect of 3′-deoxyadenosine (Figure 2b). Similarly, the suppressive effect of 3′-deoxyadenosine on the induction of collagens by BMP-4 was reversed by MRS1523 and NBTI, whereas DPSPX did not affect the suppressive effect of 3′-deoxyadenosine (Figure 2c and Supplementary Figure S3b). The suppressive effect of 3′-deoxyadenosine on BMP-4-triggered BRE activation was also reversed by MRS1523 and NBTI, but not by DPSPX (Figure 2d). Treatment with agonist of adenosine A3 receptor Cl-IB-MECA significantly reduced BRE activation triggered by BMP-4 (Figure 2e). Consistent with these results using pharmacological inhibitors, knockdown of the A2B adenosine receptor by siRNA had little impacts on the suppressive effects of 3′-deoxyadenosine on TGF-β1- and BMP-4-induced activation of the CAGA box and BRE (Supplementary Figures S4a and S4b, left). In contrast, knockdown of the A3 receptor partially reversed the suppressive effect of 3′-deoxyadenosine on BMP-4-induced BRE activation, but not on TGF-β1-induced activation of the CAGA box (Supplementary Figures S4a and S4b, right).
Reduction in the Level of Smad Proteins by 3′-Deoxyadenosine
Phosphorylation of Smad proteins has central roles in TGF-β and BMP signaling.11 To elucidate mechanisms underlying the suppressive effects of 3′-deoxyadenosine on the TGF-β and BMP-4 pathways, we tested effects of 3′-deoxyadenosine on the phosphorylation of Smad proteins. When cells were treated with TGF-β1, phosphorylation of Smad2 and Smad3 was observed. The basal and inducible phosphorylation of Smad3 was substantially suppressed by the treatment with 3′-deoxyadenosine (Figure 3a and Supplementary Figure S5). Phosphorylation of Smad2 was also inhibited modestly by 3′-deoxyadenosine. Interestingly, levels of total Smad2 and Smad3 proteins, especially Smad3, were depressed by the treatment with 3′-deoxyadenosine (Figure 3a and Supplementary Figure S5). Similarly, when cells were treated with BMP-4, phosphorylation of Smad1 was observed, and the basal and phosphorylated Smad1 was reduced by the treatment with 3′-deoxyadenosine (Figure 3b, and Supplementary Figure S6). Like Smad3, the level of total Smad1 was also reduced by the treatment with 3′-deoxyadenosine. The suppressive effects of 3′-deoxyadenosine on Smads were not specific to NRK-52E cells, and similar effects were also observed in rat mesangial cells (Figures 3c and d).
Consistent with the lack of effects of adenosine on TGF-β1- and BMP-4-induced activation of the CAGA box and BRE (Figures 1f and g), TGF-β1- and BMP-4-induced phosphorylation of Smad1, Smad2 and Smad3 were not affected by adenosine. The levels of total Smad proteins were also unaffected by the treatment with adenosine (Supplementary Figures S7a and S7b).
Lack of eIF2α-mediated Translational Suppression for the Effect of 3′-Deoxyadenosine
The down regulation of Smad proteins may be caused by enhanced protein degradation or translational suppression. To examine the former possibility, cells were treated with 3′-deoxyadenosine in the absence or presence of proteasome inhibitor MG132 or lysosome inhibitor chloroquine. Western blot analysis showed that both MG132 and chloroquine failed to reverse the inhibitory effects of 3′-deoxyadenosine on Smad proteins (Figures 4a and b). Of note, the concentration of MG132 was sufficient to inhibit proteasome function, because MG132 efficiently inhibited degradation of connexin 43 in NRK-52E cells (our unpublished data). Similarly, the concentration of chloroqiune was sufficient to inhibit autophagy (data not shown).
As we recently reported,22 3′-deoxyadenosine rapidly induces phosphorylation of eIF2α that causes translational suppression (Figure 4c). Induction of the eIF2α pathway may be involved in the downregulation of Smads by 3′-deoxyadenosine. Indeed, treatment with salubrinal, an inhibitor of eIF2α dephosphorylation, reduced the levels of all Smad proteins (Figure 4d). However, activation of eIF2α was found not to be the primary mechanism, because functional knockdown of eIF2α by a eIF2α-DN or GADD34 that dephosphorylates eIF2α did not affect the suppressive effect of 3′-deoxyadenosine on TGF-β1-induced activation of the CAGA box (Figure 4e). Similarly, functional inhibition of eIF2α by eIF2α-DN or GADD34 did not reverse the suppressive effect of 3′-deoxyadenosine on BMP-4-induced activation of BRE (Figure 4f). Of note, transfection with eIF2α-DN significantly inhibited activation of CCAAT/enhancer-binding protein via the eIF2α pathway.38 Transfection with GADD34 also significantly reversed suppressive effects of salubrinal on p21CIP1/WAF1 (our unpublished data).
Transcriptional Suppression of Smads by 3′-Deoxyadenosine
As described, the downregulation of Smad proteins by 3′-deoxyadenosine was ascribed neither to enhanced degradation nor to translational suppression via eIF2α. To examine another possibility, we tested an effect of 3′-deoxyadenosine on the steady-state level of Smad mRNAs. Northern blot analysis revealed that 3′-deoxyadenosine substantially reduced the levels of Smad mRNAs in both time- and dose-dependent manners (Figures 5a and b). Consistent with the results of reporter assays for CAGA and BRE activity (Figures 2b and d), downregulation of Smad mRNAs by 3′-deoxyadenosine was reversed by the treatment with NBTI, whereas DPSPX had little impacts (Figure 5c). Downregulation of Smad1 by 3′-deoxyadenosine was reversed partially by MRS1523, whereas downregulation of Smad2 and Smad3 was unaffected (Figure 5c). The suppressive effects of 3′-deoxyadenosine on Smad mRNAs were not specific to NRK-52E cells, and similar effects were also observed in rat mesangial cells (Figure 5d).
The downregulation of Smad mRNAs may be caused by transcriptional suppression or enhanced degradation of mRNAs. To examine the latter possibility, cells were treated with actinomycin D, an inhibitor of RNA synthesis, in the absence or presence of 3′-deoxyadenosine. Northern blot analysis showed that actinomycin D caused degradation-dependent decreases in Smads, and the degradation of Smad mRNAs was not reinforced by the treatment with 3′-deoxyadenosine (Figure 5e). This result suggested that 3′-deoxyadenosine downregulated Smad mRNAs via transcriptional inhibition. To confirm this conclusion, we examined an effect of 3′-deoxyadenosine on the activity of the Smad1 gene promoter. The result showed that 3′-deoxyadenosine significantly suppressed Smad1 promoter activity (Figure 5f), confirming our conclusion.
In Vivo Suppression of Smad Signaling by 3′-Deoxyadenosine
To examine whether the level of Smads is depressed by 3′-deoxyadenosine in vivo, mice were subjected to severe UUO, an experimental model of renal fibrosis, with or without administration of 3′-deoxyadenosine. That is, sham-operated and ureter-ligated mice were treated everyday with PBS or 3′-deoxyadenosine, and after 3 days, kidneys were subjected to analyses. Northern blot analysis revealed that Smad mRNAs were induced by UUO, and the induction was suppressed by the treatment with 3′-deoxyadenosine (Figure 6a). Western blot analysis also showed that both phosphorylated and total Smad proteins (except for total Smad3) increased by UUO, and it was attenuated by administration with 3′-deoxyadenosine (Figure 6b). Consistent with this result, expression of type I collagen was markedly upregulated by UUO, and it was suppressed by the treatment with 3′-deoxyadenosine (Figure 6c). Quantitative analysis of fibrotic region confimed reduction in fibrosis by the treatment with 3′-deoxyadenosine (Figure 6d). Similarly, western blot analysis also showed that the level of α-SMA, a downstream target of Smad signaling and a marker of fibrogenesis,39, 40 was induced by UUO, and it was attenuated by 3′-deoxyadenosine (Figure 6e). This result was further confirmed using immunohistochemical analysis. As shown in Figure 6f, α-SMA increased in the renal interstitium in the UUO model, and it was diminished by the treatment with 3′-deoxyadenosine (Figure 6f, left). The increase in the number of α-SMA-positive myofibroblasts was also reduced by this agent (Figure 6f, right).
In our complete-ligature model of UUO, tissue damage is too severe, and 3′-deoxyadenosine failed to halt progression of renal fibrosis significantly, when examined at day 7 (data not shown). We therefore used a mild-ligature model of UUO34 to examine the effect of this agent at a later time period. In this experimental model, induction of collagen and α-SMA was mild, and treatment with 3′-deoxyadenosine modestly attenuated UUO-induced expression of type I collagen and α-SMA even at day 7 (Supplementary Figure S8).
DISCUSSION
In the present investigation, we demonstrated that 3′-deoxyadenosine interfered with the TGF-β and BMP signaling via downregulation of phosphorylated Smad1, Smad2 and Smad3. We also elucidated that the decrease in the level of phosphorylated Smads was correlated with down regulation of total Smad proteins, which was caused by transcriptional suppression. Previous reports indicated that 3′-deoxyadenosine may inhibit transcriptional events via multiple mechanisms.41, 42 It inhibits mRNA polyadenylation, possibly, by acting as a chain terminator.42 3′-Deoxyadenosine may also inhibit incorporation of uridine into mRNA at high doses.41 The suppression of Smad mRNAs by 3′-deoxyadenosine, observed in this report, may be through the similar mechanisms on mRNAs. However, based on our experience, individual mRNAs have different susceptibility and response to 3′-deoxyadenosine. For example, 3′-deoxyadenosine suppresses basal and inducible expression of an array of endogenous genes, whereas house-keeping gene promoter- and viral gene promoter-driven transcription may be paradoxically upregulated by this agent (manuscript in submission). In differentiating preadipocytes, 3′-deoxyadenosine rather upregulates expression of monocyte chemoattractant protein 1.22 These results are consistent with a recent report showing different sensitivity of different mRNAs to 3′-deoxyadenosine.17 The effect of 3′-deoxyadenosine on transcriptional events is not so simple as was previously proposed, and Smad mRNAs may be preferential targets of this agent to inhibit transcription.
In the present study, we showed that the inhibitory effects of 3′-deoxyadenosine on Smad mRNAs were mediated by adenosine transporter. A previous report suggested that 3′-deoxyadenosine 5′-triphosphate inhibited chromatin-associated poly(A) synthesis.43 3′-Deoxyadenosine 5′-triphosphate might be an active entity responsible for the inhibitory effects of 3′-deoxyadenosine. Conversion of 3′-deoxyadenosine to 3′-deoxyadenosine 5′-triphosphate occurs intracellularly. Transport of extracellular 3′-deoxyadenosine into the cells should be essential for the generation of 3′-deoxyadenosine 5′-triphosphate. It may be the reason why inhibition of adenosine transporter abrogated the suppressive effect of 3′-deoxyadenosine on Smad mRNAs. Interestingly, however, the suppressive effect of 3′-deoxyadenosine on Smad1 was also mediated by the A3 adenosine receptor. Currently, it is unclear how activation of the A3 receptor causes suppression of Smad1 and BRE activation, but it is consistent with our recent report showing that, in addition to the adenosine transporter, the A3 receptor was also involved in the suppression of stress marker induction by 3′-deoxyadenosine under endoplasmic reticulum stress.22
Regarding the role of the A3 receptor, the majority of our current data are consistent; ie, it mediates the suppressive effect of 3′-deoxyadenosine on the Smad1–BRE signaling, but not its effect on the Smad2/3–CAGA box pathway. Only one exception is that inhibition of the A3 receptor by MRS1523 reversed the suppressive effect of 3′-deoxyadenosine on TGF-β-triggered induction of collagens. We found that both MRS1523 and NBTI reversed the suppressive effects of 3′-deoxyadenosine on type I and type IV collagen mRNAs. It indicates that some signaling pathway other than Smad2/3–CAGA box is also involved in the induction of collagens by TGF-β and that 3′-deoxyadenosine inhibits the putative signaling via ligation of the A3 adenosine receptor.
In the present study, we showed that, compared with Smad1 and Smad3, the level of Smad2 protein was relatively preserved after the treatment with 3′-deoxyadenosine, although Smad2 mRNA was similarly suppressed by this agent. A previous report suggested that Smad3, but not Smad2, was susceptible to ubiquitin/proteasome-dependent protein degradation.44 It may result in decreased stability of Smad3 when compared with Smad2. It is worthwhile to note that Smad3 is considered as a dominant mediator for the induction of fibrogenic processes. For example, Smad3-deficient mice are resistant to interstitial fibrosis triggered by UUO.45 Using siRNA to achieve selective knockdown of Smad2 and Smad3, Phanish et al.46 found that induction of connective tissue growth factor by TGF-β was Smad3 dependent, but independent of Smad2 in renal tubular cells. 3′-Deoxyadenosine could interfere with the TGF-β signaling through preferential suppression of Smad3, although there was some discrepancy between the in vitro data and in vivo results.
Smad signaling has been considered as a master switch for the induction of tissue fibrosis. Previous reports demonstrated that the Smad pathways were crucial for the induction of collagen genes.47, 48 Smads also mediate negative effects of TGF-β on matrix metalloproteinases and its positive effects on tissue inhibitor of metalloproteinases, contributing to fibrogenesis.49, 50 In the present report, we demonstrated that in vivo administration with 3′-deoxyadenosine reduced the levels of phosphorylated and total Smad proteins, as well as Smad mRNAs in the kidney subjected to UUO. It was associated with attenuated induction of interstitial-type collagen and α-SMA, the downstream targets of Smad signaling, in the kidney. Our current results indicate that 3′-deoxyadenosine interferes with the profibrotic Smad signaling and could be useful for the treatment of fibrogenic disorders.
References
Das SK, Masuda M, Sakurai A et al. Medicinal uses of the mushroom Cordyceps militaris: current state and prospects. Fitoterapia 2010;81:961–968.
Zhu JS, Halpern GM, Jones K . The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis: part II. J Altern Complement Med 1998;4:429–457.
Schnaper HW, Hayashida T, Poncelet AC . It’s a Smad world: regulation of TGF-β signaling in the kidney. J Am Soc Nephrol 2002;13:1126–1128.
Eddy AA . Molecular basis of renal fibrosis. Pediatr Nephrol 2000;15:290–301.
Hills CE, Squires PE . TGF-β1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010;31:68–74.
Mizutani M, Ito Y, Mizuno M et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol 2010;298:F721–F733.
Tominaga T, Abe H, Ueda O et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem 2011;22:20109–20116.
Miyazawa K, Shinozaki M, Hara T et al. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 2002;7:1191–1204.
Derynck R, Zhang YE . Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577–584.
Liu Y . New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212–222.
Dennler S, Itoh S, Vivien D et al. Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091–3100.
Korchynskyi O, ten Dijke P . Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 2002;277:4883–4891.
Bauerle JD, Grenz A, Kim JH et al. Adenosine generation and signaling during acute kidney injury. J Am Soc Nephrol 2011;22:14–20.
Yap SC, Lee HT . Adenosine and protection from acute kidney injury. Curr Opin Nephrol Hypertens 2012;21:24–32.
Cunningham KG, Manson W, Spring FS et al. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.) Link. Nature 1950;166:949–949.
Kaczka EA, Trenner NR, Arison B et al. Identification of cordycepin, a metabolite of Cordyceps militaris, as 3′-deoxyadenosine. Biochem Biophys Res Commun 1964;14:456–457.
Wong YY, Moon A, Duffin R et al. Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem 2010;285:2610–2621.
Jagger DV, Kredich NM, Guarino AJ . Inhibition of Ehrlich mouse ascites tumor growth by cordycepin. Cancer Res 1960;21:216–220.
Kim HG, Shrestha B, Lim SY et al. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-kappaB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur J Pharmacol 2006;545:192–199.
Nan JX, Park EJ, Yang BK et al. Antifibrotic effect of extracellular biopolymer from submerged mycelial cultures of Cordyceps militaris on liver fibrosis induced by bile duct ligation and scission in rats. Arch Pharm Res 2001;24:327–332.
Li L, He D, Yang J et al. Cordycepin inhibits renal interstitial myofibroblast activation probably by inducing hepatocyte growth factor expression. J Pharmacol Sci 2011;117:286–294.
Kitamura M, Kato H, Saito Y et al. Aberrant, differential and bidirectional regulation of the unfolded protein response towards cell survival by 3′-deoxyadenosine. Cell Death Differ 2011;18:1876–1888.
Kadomatsu M, Nakajima S, Kato H et al. Cordycepin as a sensitizer to TNF-α-induced apoptosis through eIF2α- and mTORC1- mediated inhibition of NF-κB. Clin Exp Immunol 2012;168:325–332.
Kitamura M, Taylor S, Unwin R et al. Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo. J Clin Invest 1994;94:497–505.
Oberbaumer I, Laurent M, Schwarz U et al. Amino acid sequence of the non-collagenous globular domain (NC1) of the α1(IV) chain of basement membrane collagen as derived from complementary DNA. Eur J Biochem 1985;147:217–224.
Chu ML, Myers JC, Bernard MP et al. Cloning and characterization of five overlapping cDNAs specific for the human proα1(I) collagen chain. Nucleic Acids Res 1982;10:5925–5934.
McHugh KM, Lessard JL . The nucleotide sequence of a rat vascular smooth muscle α-actin cDNA. Nucleic Acids Res 1988;16:4167.
Nakajima S, Hiramatsu N, Hayakawa K et al. Selective abrogation of BiP/GRP78 blunts activation of NF-κB through the ATF6 branch of the UPR: involvement of C/EBPβ and mTOR-dependent dephosphorylation of Akt. Mol Cell Biol 2011;31:1710–1718.
Harding HP, Zhang Y, Scheuner D et al. Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2α (eIF2α) dephosphorylation in mammalian development. Proc Natl Acad Sci USA 2009;106:1832–1837.
Omasa T, Takami T, Ohya T et al. Overexpression of GADD34 enhances production of recombinant human antithrombin III in Chinese hamster ovary cells. J Biosci Bioeng 2008;106:568–573.
Sun Y, Fan J, Shen H et al. Cloning and promoter activity of rat Smad1 5′-flanking region in rat hepatic stellate cells. Mol Cell Biochem 2007;304:227–234.
Hiramatsu N, Kasai A, Hayakawa K et al. Real-time detection and continuous monitoring of ER stress in vitro and in vivo by ES-TRAP: evidence for systemic, transient ER stress during endotoxemia. Nucleic Acids Res 2006;34:e93.
Iwano M, Plieth D, Danoff MD et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341–350.
Kato H, Nakajima S, Saito Y et al. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ 2012;19:310–320.
Thornhill BA, Burt LE, Chen C et al. Variable chronic partial ureteral obstruction in the neonatal rat: A new model of ureteropelvic junction obstruction. Kidney Int 2005;67:42–52.
Zhou H, Hammonds RG, Findlay DM et al. Differential effects of transforming growth factor-β1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts. J Cell Physiol 1993;155:112–119.
Assoian RK, Komoriya A, Meyers CA et al. Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983;258:7155–7160.
Hayakawa K, Nakajima S, Hiramatsu N et al. ER stress depresses NF-κB activation in mesangial cells through preferential induction of C/EBPβ. J Am Soc Nephrol 2010;21:73–81.
Evans RA, Tian YC, Steadman R et al. TGF-β1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res 2003;282:90–100.
MacPherson BR, Leslie KO, Lizaso KV et al. Contractile cells of the kidney in primary glomerular disorders: an immunohistochemical study using an anti-α-smooth muscle actin monoclonal antibody. Hum Pathol 1993;24:710–716.
Penman S, Rosbash M, Penman M . Messenger and heterogeneous nuclear RNA in HeLa cells: differential inhibition by cordycepin. Proc Natl Acad Sci USA 1970;67:1878–1885.
Muller WE, Seibert G, Beyer R et al. Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res 1977;37:3824–3833.
Rose KM, Bell LE, Jacob ST . Specific inhibition of chromatin-associated poly(A) synthesis in vitro by cordycepin 5′-triphosphate. Nature 1977;267:178–180.
Guo X, Waddell DS, Wang W et al. Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 γ2, an inhibitor of TGF-β signaling. Oncogene 2008;27:7235–7247.
Sato M, Muragaki Y, Saika S et al. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112:1486–1494.
Phanish MK, Wahab NA, Colville-Nash P et al. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGF-β1 responses in human proximal tubule epithelial cells. Biochem J 2006;393:601–607.
Abe H, Matsubara T, Iehara N et al. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004;279:14201–14206.
Verrecchia F, Chu ML, Mauviel A . Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001;276:17058–17062.
Yuan W, Varga J . Transforming growth factor-β repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001;276:38502–38510.
Qureshi HY, Ricci G, Zafarullah M . Smad signaling pathway is a pivotal component of tissue inhibitor of metalloproteinases-3 regulation by transforming growth factor-β in human chondrocytes. Biochim Biophys Acta 2008;1783:1605–1612.
Acknowledgements
We thank Dr Keiji Miyazawa (University of Yamanashi) and Dr Atsuhito Nakao (University of Yamanashi) for their kind support and helpful comments on this work. We also appreciate kind gifts of plasmids by Dr Takahiro Taira (University of Yamanashi), Dr Takeshi Omasa (Osaka University), Dr David Ron (University of California San Francisco) and Dr Yuewen Gong (University of Manitoba), and technical support for histological analysis by Mrs Mikiko Yoda (University of Yamanashi). This work was supported, in part, by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 20390235) to MK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict interest.
Additional information
Supplementary Information accompanies the paper on the Laboratory Investigation website
Cordycepin, or 3′-deoxyadenosine, is a major nucleoside derivative isolated from the mushroom Cordyceps militaris. This compound interferes with fibrogenic processes in the kidney, suppressing TGF-β and bone morphogenetic protein signaling via down-regulation of Smads. Cordycepin may therefore be useful for therapeutic intervention in TGF-β-related fibrotic disorders.
Rights and permissions
About this article
Cite this article
Gu, L., Johno, H., Nakajima, S. et al. Blockade of Smad signaling by 3′-deoxyadenosine: a mechanism for its anti-fibrotic potential. Lab Invest 93, 450–461 (2013). https://doi.org/10.1038/labinvest.2013.4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/labinvest.2013.4